UroGen Pharma Ltd. Ordinary Shares (URGN) is a publicly traded Healthcare sector company. As of May 21, 2026, URGN trades at $29.96 with a market cap of $1.39B and a P/E ratio of -10.77. URGN moved +6.99% today. Year to date, URGN is +36.56%; over the trailing twelve months it is +300.80%. Its 52-week range spans $3.42 to $32.37. Analyst consensus is strong buy with an average price target of $39.29. Rallies surfaces URGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in URGN news today?
UroGen Raises Price Target to $39 After Q1 Sales Double to $29.2M: UroGen Pharma raised its 12-month price target to $39 and reaffirmed a Buy after Q1 2026 results showed Zusduri sales doubled quarter-over-quarter to $29.2 million driven by January J-code assignment. UroGen will present one-on-one at Bank of America on May 13, HC Wainwright on May 19 and TD Cowen on May 26.
UroGen Raises Price Target to $39 After Q1 Sales Double to $29.2M: UroGen Pharma raised its 12-month price target to $39 and reaffirmed a Buy after Q1 2026 results showed Zusduri sales doubled quarter-over-quarter to $29.2 million driven by January J-code assignment. UroGen will present one-on-one at Bank of America on May 13, HC Wainwright on May 19 and TD Cowen on May 26.
Does Rallies summarize URGN news?
Yes. Rallies summarizes URGN news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is URGN research on Rallies investment advice?
No. Rallies provides research, data, and educational context for URGN. It does not provide personalized investment advice.
